Biotech giant Amgen Inc (AMGN) bills itself as one of the first biotechnology firms. It was founded in 1980 and has grown into a firm with 20,000 employees, a market capitalization of nearly $100 billion, and approximately $20 billion in annual sales. Below is an overview of its main rivals.

Product Rivals

Any pharmaceutical or biotech firm is technically a rival to Amgen, though there is a smaller subset of rivals that sell similar drugs to Amgen. For instance, Johnson & Johnson (JNJ) sells Procrit, which is a competitor to Aranesp and Amgen’s stable of anemia treatments. Teva Pharmaceutical (TEVA) also sells an increasing array of biosimilar drugs to Aranesp Amgen’s Enbrel helps treat arthritis, which competes with AbbVie’s (ABBV) popular Humira drug. Celgene (CELG) sells Revlimid to treat myeloma and Amgen is in the process of getting into the field with the acquisition of Onyx and its Kyprolis drug, also for the treatment of myeloma.

Biotech Competition

In general, Amgen competes with other large biotech firms. Biogen Idec (BIIB) sells a number of drugs to help treat multiple sclerosis and is seeing success with the launch of a couple of drugs to treat hemophilia. Celgene sells drugs that help treat cancer and immune-inflammatory diseases. Gilead Sciences (GILD) offers a number of drugs that help patients suffering from HIV and recently released Solvadi, which has had great success in helping patients with hepatitis C infections.

The Bottom Line

A number of firms continue to muscle into Amgen’s core businesses of treating anemia, arthritis, and myeloma. Generic versions will also continue to be introduced as Amgen’s drug patents expire over time. Most investment bankers and analysts, however, still project Amgen will remain profitable over time.

At the time of writing, Ryan C. Fuhrmann is long shares of Amgen and Gilead but did not own shares in any of the other companies mentioned in this article.

  1. How does government regulation impact the drugs sector?

    Learn about how drugs are regulated by the U.S. government as well as the role of the Food and Drug Administration during ... Read Answer >>
  2. What are the differences between brand name drugs and generic drugs?

    Discover the process by which brand name drugs lose their patent, allowing generics to be manufactured, as well as the differences ... Read Answer >>
  3. What level of return on equity is average for a company in the drugs sector?

    Find out more about the drugs sector, which industries are included in the sector and the average return on equity for companies ... Read Answer >>
  4. What factors make the drug sector good for value investing?

    Discover what makes the drugs sector good for value investing. The perfect ingredient for value investors is to find undervalued ... Read Answer >>
  5. How does the drug sector benefit from the growth of emerging markets?

    Understand how the pharmaceutical industry benefits from the growth of emerging markets. Benefits are linked to growing economies ... Read Answer >>
  6. What does it mean when a company in the drug sector has orphan drugs?

    Understand what it means when a company in the pharmaceutical industry has drugs within its portfolio that are designated ... Read Answer >>
Related Articles
  1. Investing

    Analyzing Amgen's Price & Profitability Ratios in 2016 (AMGN)

    Learn about Amgen's price ratios and profitability ratios and discover why it has one of the highest profit margins in the global pharmaceutical sector.
  2. Investing

    Amgen: An Activist Investment Analysis (AMGN)

    Learn about the activist investor campaign Third Point Partners has initiated against Amgen. Read about Third Point's criticisms of Amgen.
  3. Investing

    5 Things Amgen's Management Wants You to Know (AMGN)

    With its share price already having tripled over the trailing four-year period, Amgen (NASDAQ: AMGN) delivered more solid numbers when it reported first-quarter results on April 21. Quarterly ...
  4. Insights

    Amgen’s Kyprolis Fails in Trial (AMGN)

    The failure in a comparative study has raised doubts about Amgen’s $10.4 billion takeover of the drug.
  5. Investing

    If You Had Invested Right After Amgen's IPO (AMGN)

    Discover how $1,000 invested in Amgen during its initial public offering (IPO), without reinvesting dividends, would be worth over $427,000 as of November 2015.
  6. Investing

    Biotech Stocks Are Suddenly a Bargain

    The huge drop in biotech stocks has turned many into bargains, including Amgen, Biogen and others.
  7. Investing

    Amgen Q4 Earnings Beat Street Forecasts

    Amgen's 4Q earnings and revenue beat analyst projections.
  8. Investing

    A Forecast for Amgen Trends in 2017

    Amgen had a rough 2016, but the company's pipeline of new products could drive recovery in 2017.
  9. Insights

    Long Wait for Biosimilar Amjevita (AMGN)

    While Amgen’s Humira biosimilar called Amjevita has been approved by the FDA, it will be a very long wait for real commercial benefits.
  10. Insights

    Amgen Targeting Biosimilars (AMGN)

    Amid emerging biosimilar challenges, Amgen is taking the legal route to thwart and delay competition, in addition to pursuing its own biosimilar programs.
  1. Drug

    A substance that cures, treats, prevents or reduces the symptoms ...
  2. Healthcare Sector

    The healthcare sector consists of companies that provide medical ...
  3. Abbreviated New Drug Application (ANDA)

    A written request to the U.S. Food and Drug Administration to ...
  4. Orphan Drug Credit

    A federal tax credit that provides an incentive for pharmaceutical ...
  5. Blockbuster Drug

    An extremely popular drug that generates annual sales of at least ...
  6. Phase 2

    The second phase of clinical trials or studies for an experimental ...
Trading Center